SAB Biotherapeutics (NASDAQ:SABS) Earns Buy Rating from Analysts at HC Wainwright
HC Wainwright began coverage on shares of SAB Biotherapeutics (NASDAQ:SABS – Free Report) in a report issued on Wednesday, MarketBeat reports. The brokerage issued a buy rating and a $10.00 price objective on the stock. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q2 2025 earnings at ($0.58) EPS, Q3 2025 earnings at ($0.44) EPS, […]
HC Wainwright began coverage on shares of SAB Biotherapeutics (NASDAQ:SABS – Free Report) in a report issued on Wednesday, MarketBeat reports. The brokerage issued a buy rating and a $10.00 price objective on the stock. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q2 2025 earnings at ($0.58) EPS, Q3 2025 earnings at ($0.44) EPS, […]
-inc-logo-1200x675.jpg?v=20240515130629&w=240&h=240&zc=2){kind=logo}
